Myo-Inositol for PCOS (2026): One of the Best-Evidenced PCOS Supplements
Myo-inositol is one of the genuinely well-supported PCOS supplements. It improves insulin sensitivity, helps restore ovulation and regular cycles, and improves metabolic markers — supported strongly enough to feature in the 2023 international PCOS guidelines (Fitz 2024, PMID: 38163998).
Dose: ~2g twice daily (4g/day), 40:1 myo:D-chiro ratio, ~3 months to judge. Very well tolerated.
Studied formulation: Ovasitol (40:1). Best value: Wholesome Story Myo + D-Chiro.
Why it works for PCOS
PCOS is, at its core, often a condition of insulin resistance — which drives the hormonal disruption behind irregular cycles, missed ovulation, and metabolic problems. Myo-inositol is directly involved in insulin signaling, so improving that signaling addresses a root mechanism rather than just a symptom. The evidence reflects this: across studies, myo-inositol improves insulin sensitivity, helps restore ovulation and menstrual regularity, and improves metabolic and hormonal markers in PCOS (Fitz 2024, PMID: 38163998). That it was reviewed in the international evidence-based PCOS guidelines tells you it's taken seriously — uncommon for a supplement.
The 40:1 ratio matters here
For PCOS, use a 40:1 myo-inositol to D-chiro-inositol product — the body's natural ratio and the one used in key trials (including Ovasitol). This isn't a marketing detail: excess D-chiro-inositol may actually worsen ovarian function and egg quality, so a high-D-chiro blend can be counterproductive. Pick 40:1, not "extra D-chiro."
Dose, timeline, and expectations
- Dose: ~2g myo-inositol twice daily (4g/day), 40:1 ratio.
- Timeline: cycle regularity and metabolic improvements build over weeks to ~3 months — be patient.
- Tolerability: very good; mild GI upset at most.
- Realistic: it's an evidence-supported helper, not a cure — best alongside lifestyle measures and medical care.
Myo-inositol vs metformin, and fertility
Myo-inositol and metformin target the same insulin-resistance problem; some studies show comparable PCOS improvements with myo-inositol and fewer GI side effects than metformin. Metformin has the longer regulated track record, so the choice (or using both) is best made with your doctor. For fertility, myo-inositol's main benefit is restoring ovulation — a core barrier in PCOS — and it's commonly used in fertility-support protocols, though it's not a guaranteed treatment. If you're trying to conceive, fold it into a plan with your doctor or fertility specialist.
Best myo-inositol for PCOS, ranked
| Product | Ratio | Servings | Price | Cost/Day | Buy |
|---|---|---|---|---|---|
| Wholesome Story Myo-Inositol & D-Chiro Inositol 40:1 Best Value | Myo + D-chiro (40:1) | 30 | $27.95 | $0.93 | Buy |
| Ovasitol by Theralogix 90-day supply Quality Pick | Myo + D-chiro (40:1) | 90 | $86.68 | $0.97 | Buy |
Ovasitol is the formulation matching the studied 40:1 ratio (NSF/3rd-party tested); Wholesome Story offers the same 40:1 blend at lower cost.
Frequently asked questions
Does myo-inositol help PCOS?
Yes — one of the better-evidenced PCOS supplements. Improves insulin sensitivity, ovulation, cycle regularity, and metabolic markers; reviewed in the 2023 international PCOS guidelines. Not a cure, but genuinely supported.
How much for PCOS?
~2g twice daily (4g/day), 40:1 myo:D-chiro ratio. Give it ~3 months. Well tolerated.
As good as metformin?
Targets the same insulin resistance; some studies show comparable improvements with fewer GI side effects. Metformin has the longer regulated record. Decide (or combine) with your doctor.
Helps fertility?
Mainly by restoring ovulation (a core PCOS fertility barrier); used in fertility-support protocols. Not guaranteed — work with your doctor/fertility specialist.
Related guides
Sources
- Fitz V, et al. "Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-Based PCOS Guidelines." J Clin Endocrinol Metab. 2024;109(6):1630-1655. PMID: 38163998
- Moslehi N, et al. "Effects of nutrition on metabolic and endocrine outcomes in women with PCOS." (systematic review). 2023. PMID: 36099162